← Back to Screener
MindWalk Holdings Corp. Common Stock (HYFT)
Price$1.27
Favorite Metrics
Price vs S&P 500 (26W)-35.27%
Price vs S&P 500 (4W)5.16%
Market Capitalization$45.50M
All Metrics
Book Value / Share (Quarterly)$0.23
P/TBV (Annual)1.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.19%
Cash Flow / Share (Quarterly)$-0.19
Price vs S&P 500 (YTD)-31.06%
Gross Margin (TTM)60.32%
Net Profit Margin (TTM)-66.46%
EPS (TTM)$-0.19
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-0.19
Revenue Growth (5Y)11.77%
EPS (Annual)$-0.66
ROI (Annual)-81.65%
Gross Margin (Annual)55.25%
Net Profit Margin (5Y Avg)-97.99%
Cash / Share (Quarterly)$0.22
Revenue Growth QoQ (YoY)-32.40%
ROA (Last FY)-68.03%
Revenue Growth TTM (YoY)-23.23%
EBITD / Share (TTM)$-0.20
ROE (5Y Avg)-57.82%
Operating Margin (TTM)-65.58%
Cash Flow / Share (Annual)$-0.11
P/B Ratio5.72x
P/B Ratio (Quarterly)6.97x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.04x
Net Interest Coverage (TTM)-38.07x
ROA (TTM)-36.48%
EPS Incl Extra (Annual)$-0.66
Current Ratio (Annual)2.08x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume0.44M
52-Week Price Return211.48%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.23
P/S Ratio (Annual)3.47x
Asset Turnover (Annual)0.55x
52-Week High$3.25
Operating Margin (5Y Avg)-101.70%
EPS Excl Extra (Annual)$-0.66
CapEx CAGR (5Y)10.37%
26-Week Price Return-26.52%
Quick Ratio (Annual)1.72x
13-Week Price Return-37.85%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)3.74x
Enterprise Value$54.582
Revenue / Share Growth (5Y)-6.57%
Asset Turnover (TTM)0.55x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)5.18x
Pretax Margin (Annual)-139.75%
Cash / Share (Annual)$0.17
3-Month Return Std Dev93.30%
Gross Margin (5Y Avg)56.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-127.97%
Net Interest Coverage (Annual)-43.42x
EPS Basic Excl Extra (Annual)$-0.66
P/FCF (TTM)95.53x
Receivables Turnover (TTM)4.91x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-0.19
Receivables Turnover (Annual)5.62x
ROI (TTM)-48.39%
P/S Ratio (TTM)4.62x
Pretax Margin (5Y Avg)-101.28%
Revenue / Share (Annual)$0.54
Tangible BV / Share (Annual)$0.36
Price vs S&P 500 (52W)176.38%
Year-to-Date Return-26.92%
5-Day Price Return22.02%
EPS Normalized (Annual)$-0.66
ROA (5Y Avg)-35.25%
Net Profit Margin (Annual)-123.30%
Month-to-Date Return17.70%
EBITD / Share (Annual)$-0.69
Operating Margin (Annual)-136.87%
LT Debt / Equity (Annual)0.03x
ROI (5Y Avg)-42.63%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.19
P/TBV (Quarterly)6.97x
P/B Ratio (Annual)1.16x
Inventory Turnover (TTM)6.07x
Pretax Margin (TTM)-71.76%
Book Value / Share (Annual)$0.37
Price vs S&P 500 (13W)-40.72%
Beta0.76x
Revenue / Share (TTM)$0.29
ROE (TTM)-63.66%
52-Week Low$0.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. Common Stock | 4.62x | -23.23% | 60.32% | — | $1.27 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
MindWalk Holdings Corp is a bio-native AI company that accelerates drug discovery and development using proprietary HYFT technology and its LensAI platform. The company integrates molecular sequence, structure, function, and literature data into a unified computational framework, paired with an internal wet lab for validation. This integrated approach enables rapid applications in epitope mapping, protein design, vaccine exploration, and large-scale biologics analysis, helping to advance drug candidates faster from discovery to validation.